北京大学医学部 临床博士
北京大学肿瘤医院胸部肿瘤内一科 副主任医师
北京医学奖励基金会肺癌青年委员会秘书
CSCO青年专家委员
北京肿瘤学会肺癌专委会委员
国家远程医疗与互联网医学中心肺癌专委会常委
北京健康促进会肺癌诊疗专家委员会委员
中国老年学学会委员
中国女医师协会委员
第一负责人主持吴阶平基金1项
近5年第一/共同第一作者发表SCI论文9篇，累计影响因子>60
第五届”35 under 35”优秀青年肿瘤医生
“百例飞扬”肺癌免疫治疗病例挑战赛冠军
菁彩肺扬肺癌病例挑战赛冠军
发表论文
英文文章
1.Minglei Zhuo*, Yanfang Guan*, Xue Yang*,et al. The Prognostic and
Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in
Pulmonary Large-Cell Neuroendocrine Carcinoma, Clinical Cancer Research,2020.2
.
2.Zhou X*,Jiang J*,Yang X* , et al. First-in-human evaluation of a
PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with
PET. J Nucl Med. 2022 Apr;63(4):536-542.
3.Irfan C,Yang X*, et al. ALK-TKI therapy in patients with ALK-positive
non-small cell lung cancer and brain metastases: A review of the literature and
local experiences.Crit Rev Oncol Hematol. 2022 Dec;180:103847.
4.Zhang T, Yang X, Zhao J,et al.The Application of Combined Immune Checkpoint
Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients
and the Associations There of With the Lung Immune Prognostic Index. Front.
Oncol. 2021 Jun 4;11:690093.
5.Yang X, Xia Y, Xu L, ,et al. Efficacy and Safety of Combination Treatment
With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth
Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of
a Multicenter Clinical Study. Front. Mol. Biosci. 2021, 8:639892.
6.Xue Yang, Huang Chuan,Rongrong Chen,et al. Resolving Resistance to
Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q
Mutation,Clin Lung Cancer. 2020 Jul;21(4):e258-e260.
7.Xue Yang, Minglei Zhuo, Anhui Shi, et al.Optimal first-line treatment for
advanced thymic carcinoma, Thorac Cancer. 2019 Nov;10(11):2081-2087.
8.Huang C, Yang X. Simultaneous tongue metastasis from malignant pleural
mesothelioma: Case report and literature review. Thorac Cancer. 2020 Dec
1;12(3):391-396.
中文文章
1. 杨雪, 赵军. EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展. 中国肺癌杂志, 2022, 25(5):337-350.
2. 杨雪、赵军等. 非小细胞肺癌的个体化治疗进展.中国肺癌杂志.2022, 25(3):C1-18.
3. 杨雪, 赵军. 1例EGFR突变晚期非小细胞肺癌患者靶向治疗策略探讨.中国肿瘤临床, 2021, 48(10):3.
4. 黄川, 杨雪. 非小细胞肺癌免疫治疗生物标志物的研究进展.中国肺癌杂志, 2021, 24(11):7.
5. 杨雪; 陈含笑; 张弘等NSCLC携带EGFR少见突变分析及EGFR-TKIs疗效初步观察，中国肺癌杂志, 2015.8,
18(08):493~499
